Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection

被引:1
作者
Morton, Ernest [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [3 ]
Chang, Peter [3 ]
Wagner, Andrew [3 ]
Kim, Simon P. [4 ]
Bellmunt, Joaquim [5 ]
Kaplan, Irving [6 ]
Olumi, Aria F. [3 ]
Gershman, Boris [3 ]
机构
[1] Western Michigan Univ, Homer Stryker MD Sch Med, Kalamazoo, MI USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[4] Univ Colorado Anschutz, Med Ctr, Div Urol, Aurora, CO USA
[5] Beth Israel Deaconess Med Ctr, Dept Med, Div Med Oncol, Boston, MA USA
[6] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA USA
关键词
Bladder cancer; Lymph node; Lymphadenopathy; Metastasis; Lymph node dissection; RADICAL CYSTECTOMY; OPEN-LABEL; CANCER; CHEMOTHERAPY; MULTICENTER;
D O I
10.1016/j.urolonc.2022.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Although pathologic lymph node involvement carries a poor prognosis in patients with urothelial carcinoma of the bladder (UCB), a subset of patients may demonstrate durable survival following surgical resection. To this end, there are limited contemporary data describing the natural history of UCB in patients with isolated lymph node involvement (cN0pN+) following radical cystectomy (RC) with pelvic lymph node dissection (PLND). We therefore utilized a large, nationwide oncology dataset to examine the natural history and outcomes of cN0 pN+ UCB after surgical resection. Materials and Methods: We identified patients in the National Cancer Database (NCDB) with cN0 pN+ cM0 UCB from 2006 to 2015 treated with RC and PLND. The associations of baseline characteristics with all-cause mortality (ACM) were evaluated using Cox regression. Results: A total of 2,884 patients formed the study cohort, including 42% with pN1 and 58% with pN2-3 disease. Of these, 606 (21%) received multiagent neoadjuvant chemotherapy, while 1,172 (41%) received postoperative adjuvant chemotherapy. A median of 15 (IQR 9-23) LNs were removed during PLND. The 5-and 7-year OS for the entire cohort were 20% and 17%, respectively. Compared to the overall cohort, patients surviving <= 5 years had lower pN stage (59% vs. 42% pN1) and lower pT stage (41% vs. 22% <= pT2). On multivariable analysis, higher pT stage (HR 2.85, 95% CI 1.52-5.36 for pT3, HR 3.27, 95% CI 1.73-6.18 for pT4 vs. pT0), higher pN stage (HR 1.17, 95% CI 1.05-1.31 for pN2-3 vs. pN1), and increasing LN density (HR 2.37, 95% CI 1.88-2.99) were most strongly associated with increased ACM, while receipt of adjuvant chemotherapy (HR 0.61, 95% CI 0.55-0.68) was associated with reduced ACM. Conclusions: Although OS for patients with cN0 pN+ M0 UCB is poor, a subset of patients demonstrates durable long-term survival with 5-and 7-year OS of 20% and 17%, respectively. pT and pN stage represent important prognostic characteristics, while administration of adjuvant chemotherapy represents a potential therapeutic intervention associated with improved ACM. (c) 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255.e7 / 255.e14
页数:8
相关论文
共 16 条
[1]   Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [J].
Bajorin, D. F. ;
Witjes, J. A. ;
Gschwend, J. E. ;
Schenker, M. ;
Valderrama, B. P. ;
Tomita, Y. ;
Bamias, A. ;
Lebret, T. ;
Shariat, S. F. ;
Park, S. H. ;
Ye, D. ;
Agerbaek, M. ;
Enting, D. ;
McDermott, R. ;
Gajate, P. ;
Peer, A. ;
Milowsky, M., I ;
Nosov, A. ;
Antonio Jr, J. N. ;
Tupikowski, K. ;
Toms, L. ;
Fischer, B. S. ;
Qureshi, A. ;
Collette, S. ;
Unsal-Kacmaz, K. ;
Broughton, E. ;
Zardavas, D. ;
Koon, H. B. ;
Galsky, M. D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (22) :2102-2114
[2]   Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial [J].
Bellmunt, Joaquim ;
Hussain, Maha ;
Gschwend, Jurgen E. ;
Albers, Peter ;
Oudard, Stephane ;
Castellano, Daniel ;
Daneshmand, Siamak ;
Nishiyama, Hiroyuki ;
Majchrowicz, Martin ;
Degaonkar, Viraj ;
Shi, Yi ;
Mariathasan, Sanjeev ;
Grivas, Petros ;
Drakaki, Alexandra ;
O'Donnell, Peter H. ;
Rosenberg, Jonathan E. ;
Geynisman, Daniel M. ;
Petrylak, Daniel P. ;
Hoffman-Censits, Jean ;
Bedke, Jens ;
Kalebasty, Arash Rezazadeh ;
Zakharia, Yousef ;
van der Heijden, Michiel S. ;
Sternberg, Cora N. ;
Davarpanah, Nicole N. ;
Powles, Thomas .
LANCET ONCOLOGY, 2021, 22 (04) :525-537
[3]   Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy [J].
Cha, Eugene K. ;
Sfakianos, John P. ;
Sukhu, Ranjit ;
Yee, Alyssa M. ;
Sjoberg, Daniel D. ;
Bochner, Bernard H. .
BJU INTERNATIONAL, 2018, 122 (04) :627-632
[4]   Treatment of muscle-invasive bladder cancer: A systematic review [J].
Chou, Roger ;
Selph, Shelley S. ;
Buckley, David I. ;
Gustafson, Katie S. ;
Griffin, Jessica C. ;
Grusing, Sara E. ;
Gore, John L. .
CANCER, 2016, 122 (06) :842-851
[5]   Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial [J].
Cognetti, F. ;
Ruggeri, E. M. ;
Felici, A. ;
Gallucci, M. ;
Muto, G. ;
Pollera, C. F. ;
Massidda, B. ;
Rubagotti, A. ;
Giannarelli, D. ;
Boccardo, F. .
ANNALS OF ONCOLOGY, 2012, 23 (03) :695-700
[6]   Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base [J].
Cohen, Andrew J. ;
Packiam, Vignesh ;
Nottingham, Charles ;
Steinberg, Gary ;
Smith, Norm D. ;
Patel, Sanjay .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (01) :34.e1-34.e8
[7]   Outcome after radical cystectomy with limited or extended pelvic lymph node dissection [J].
Dhar, Nivedita Bhatta ;
Klein, Eric A. ;
Reuther, Alwyn M. ;
Thalmann, George N. ;
Madersbacher, Stephan ;
Studer, Urs E. .
JOURNAL OF UROLOGY, 2008, 179 (03) :873-878
[8]   Current controversies on the role of lymphadenectomy for bladder cancer [J].
Ghodoussipour, Saum ;
Daneshmand, Siamak .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (03) :193-200
[9]   Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial [J].
Gschwend, Juergen E. ;
Heck, Matthias M. ;
Lehmann, Jan ;
Ruebben, Herbert ;
Albers, Peter ;
Wolff, Johannes M. ;
Frohneberg, Detlef ;
de Geeterg, Patrick ;
Heidenreich, Axel ;
Kaelble, Tilman ;
Stoeckle, Michael ;
Schnoeller, Thomas ;
Stenzl, Arnulf ;
Mueller, Markus ;
Truss, Michael ;
Roth, Stephan ;
Liehr, Uwe-Bernd ;
Leissner, Joachim ;
Bregenzer, Thomas ;
Retz, Margitta .
EUROPEAN UROLOGY, 2019, 75 (04) :604-611
[10]   THE RATIONALE FOR EN-BLOC PELVIC LYMPH-NODE DISSECTION FOR BLADDER-CANCER PATIENTS WITH NODAL METASTASES - LONG-TERM RESULTS [J].
LERNER, SP ;
SKINNER, DG ;
LIESKOVSKY, G ;
BOYD, SD ;
GROSHEN, SL ;
ZIOGAS, A ;
SKINNER, E ;
NICHOLS, P ;
HOPWOOD, B .
JOURNAL OF UROLOGY, 1993, 149 (04) :758-765